Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors
Thierry André(Sorbonne Université), Susana Banerjee(Royal Marsden NHS Foundation Trust), Giuseppe Curigliano(European Institute of Oncology), Víctor Moreno, Filippo de Braud(University of Milan), Renaud Sabatier(Centre National de la Recherche Scientifique), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Valentina Boni, Jennifer Veneris, Dominique Berton(Institut de Cancérologie de l'Ouest), Susan Ellard(Kelowna General Hospital), Grace Antony(University of Hertfordshire), A. Antón Torres(Hospital Universitario Miguel Servet), Cyril Abdeddaim(Centre Oscar Lambret), Vanessa Samouëlian(Centre Hospitalier de l’Université de Montréal), José Trigo(Heidelberg University), Rowan Miller(University College Hospital), Ana Oaknin(Vall d'Hebron Institute of Oncology), Lucy Gilbert(McGill University Health Centre), Jubilee Brown(Levine Cancer Institute), Anna V. Tinker(BC Cancer Agency), Ninad Dewal, Eleftherios Zografos, Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Christine Dabrowski, Yann Vano(Délégation Paris 5)
Cited by 120
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k